Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04110561
Recruitment Status : Completed
First Posted : October 1, 2019
Last Update Posted : October 7, 2019
Sponsor:
Information provided by (Responsible Party):
Wandercraft

Tracking Information
First Submitted Date  ICMJE September 26, 2019
First Posted Date  ICMJE October 1, 2019
Last Update Posted Date October 7, 2019
Actual Study Start Date  ICMJE May 5, 2018
Actual Primary Completion Date November 16, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 27, 2019)
The primary endpoint of the clinical investigation is defined by the success or failure at the 10 Meter Walk Test (10mWT) at the latest session. [ Time Frame: At study completion, up to 3 weeks ]
The 10mWT is used to assess walking speed in meters/second (m/s) over a short distance. A clear pathway of at least 10-meter length is drawn. The start and the end point of a 10-m walkway is marked by lines. The patient starts a few steps prior the starting line; during the few steps needed to reach the starting line, the physiotherapist should stabilize the exoskeleton in the frontal plane. When the patient's first foot crosses the starting line, the test begins, and the stopwatch is started. The stopwatch is stopped at the end of the 10 meters in case of success, that is to say when the patient crosses the end line. The total time taken to ambulate is recorded. The distance covered is then divided by the total time (in seconds) taken to ambulate and recorded in meters per seconds. In case of failure, the distance walked by the patient is measured and recorded, and the speed to walk this distance is calculated as described above.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 2, 2019)
  • Capacity of patient in walking defined by Success / Failure on a 10mWT test at the 6th session. [ Time Frame: At study mid-term, 10 days in average ]
  • The maximum distance walked during the 10mWT at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • The average walking speeds during the 10mWT at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Capacity of the patient to perform verticalization as defined by the test "Stand-up" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Capacity of a standing patient to reach a sitting position as defined by the test "Sit down" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to maintain a stand still position for 2 minutes as defined by the test "Stand without support for 2 minutes" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to lean with extended arm in a standing position (90° arms) at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to perform a U-turn in less than 3 minutes as defined by the test "Make a U-turn" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Average scores on Borg CR-10 simple perception scale for the perceived exertion at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
    Rating of perceived exertion (RPE) is a widely used and reliable indicator to monitor and guide exercise intensity. The scale allows individuals to subjectively rate their level of exertion during exercise or exercise testing. Developed by Gunnar Borg, it is often also referred to as the Borg Scale. Despite being a subjective measure of exercise intensity, RPE scales provide valuable information when used correctly. The revised category-ratio scale (0 to 10 scale) is used:
    • 0 Null
    • 1 Very easy
    • 2 Somewhat easy
    • 3 Moderate
    • 4 Somewhat hard
    • 5 Hard
    • 6
    • 7 Very hard
    • 8
    • 9
    • 10 Very, very hard
  • Average scores of safety perceived by the patient on a 7-point Likert scale 7 levels at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
    A Likert scale is a psychometric scale commonly involved in research based on survey questionnaires. Here, the respondents specify their level of agreement or disagreement using a symmetric agree-disagree scale for a series of statements while responding to a particular Likert questionnaire item. The range of Likert scale captures the intensity of their feelings for a given item. The Likert scale ratings are:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
    The perceived safety is evaluated with the 7-point Likert scale on the following statement: "I felt safe during the test"
  • Observation of the skin condition was made before and after each session on the subject's back, thighs, knees and feet. [ Time Frame: Throughout study completion, an average of 3 weeks ]
  • Comparison of the NBD score before the 1st session and after the 12th session. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The neurogenic bowel dysfunction score is a questionnaire including questions about background parameters, faecal incontinence, constipation, obstructed defecation, and impact on quality of life. The NBD score is constructed from items with acceptable reproducibility and validity that were significantly associated with impact on quality of life. The type of the stool depends on the time it spends in the colon.
  • Comparison of the Bristol scale before the 1st session and after the 12th session. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Bristol Stool Chart is:
    • Type 1: Separate hard lumps, like nuts (hard to pass);
    • Type 2: Sausage-shaped but lumpy;
    • Type 3: Like a sausage but with cracks on its surface;
    • Type 4: Like a sausage or snake, smooth and soft;
    • Type 5: Soft blobs with clear-cut edges (passed easily);
    • Type 6: Fluffy pieces with ragged edges, a mushy stool;
    • Type 7: Watery, no solid pieces. Entirety liquid.
    Type 1, 2 and 3 indicate constipation. Type 4 and 5 are ideal stools. Type 6 and 7 indicate diarrhea and urgency.
  • Definition of the voiding mode at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The management of neurogenic bladder dysfunction is crucial in the management of paraplegic patients as it affects the morbidity of these patients. The voiding mode is described. The self-survey is the standard treatment when the subject has an overactive bladder. The mictionnel mode will be informed before the first session, and at the end of the last session with the exoskeleton using an ISCOS questionnaire (International Spinal Cord Society questionnaire).
  • Qualiveen score at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Qualiveen score is developed as a condition-specific quality of life measurement for individuals with SCI who have urinary disorders. It contains 4 domains:
    • Limitation/ Inconvenience;
    • Constrains/ Restrictions;
    • Fears;
    • Feelings/ Impact on Daily Life.
    The test-retest reliability is high6.
  • Spasticity according to the Modified Ashworth scale at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Modified Ashworth Scale measures spasticity in patients with lesion of the Central Nervous System. The relationship between the raters' judgments was significant and the reliability was good. (PMID: 3809245) The scoring is:
    • 0: No increase in muscle tone
    • 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
    • 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
    • 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    • 3: Considerable increase in muscle tone, passive movement difficult
    • 4: Affected part(s) rigid in flexion or extension
    Muscles evaluated are adductor, hamstring, triceps sural and quadriceps.
  • Heart rate measurement at rest and after the 10mWT at the 1st, 6th and 12th sessions. [ Time Frame: At study start, day 1, at study mid-term, 10 days and at study completion, up to 3 weeks ]
  • Comparison of the Visual Analogue Pain Scale at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Numeric Pain Rating Scale measures the subjective intensity of pain. The NPRS is an 11-points scale from 0 to 10: "0" = no pain; "10" = the most intense pain imaginable. The subject is asked to make pain rating corresponding to the current pain experienced.
  • Comparison of the NPSI scores at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    NPSI (Neuropathic Pain Sumptom Inventory) renders it suitable for the evaluation of the different dimensions of neuropathic pain syndromes. The reliability of the different descriptors appears to be sufficient. It allows to quantify the various pain symptoms that can be grouped into five dimensions (burn, deep pain, paroxysmal pain, pain caused, paresthesia / dysesthesia)
  • Patient Global Impression of Improvement (PGI-I) at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    The Patient Global Impression of Improvement (PGI-I) is a global index that may be used to rate the response of the use of Atalante on the bowel function. The subject should check the number that best describes how the twelfth session condition is, compared with how it has been at the first session for the bowel function:
    1. Very much better
    2. Much better
    3. A little better
    4. No change
    5. A little worse
    6. Much worse
    7. Very much worse
  • Average scores of the 7-point Likert scale for ergonomics at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    At the end of the twelfth session, the patient evaluates the interfaces and the ergonomics of Atalante (shape of the remote, mode, symbol) and the perceived safety and the level of assistance during transfer from the wheelchair to Atalante with a Likert scale. The Likert scale is a questionnaire where the subject chooses among seven-point scales:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
  • Time of installation of the patient in the exoskeleton at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
  • Assistance level for each fastener at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    The level of assistance is specified for each attachment (thigh, knee and foot straps). The levels of assistance are:
    • Without assistance;
    • With the assistance of one health professional;
    • With the assistance of two health professional.
  • Average scores of the 7-point Likert scale for exoskeleton attachment questionnaire at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    At the end of the twelfth session, the strapping system is evaluated using a 7-point Likert scale:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
  • Evaluation of sitting balance using the Boubee test at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    This test evaluates the ability of the subject to balance in sitting position during disturbances induced by movements of the upper limbs. The subject is sitting without back's support and with both feet on the ground. The subject is asked to do six tasks from the easiest to the hardest. The subject must pass the task to test the next task. The score is defined by the last passed task. The sitting balance is evaluated at the first and at the last session.
  • Adverse events collection at each session. [ Time Frame: Throughout study completion, an average of 3 weeks ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 27, 2019)
  • Capacity of patient in walking defined by Success / Failure on a 10mWT test at the 6th session. [ Time Frame: At study mid-term, 10 days in average ]
  • The maximum distance walked during the 10mWT at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • The average walking speeds during the 10mWT at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Capacity of the patient to perform verticalization as defined by the test "Stand-up" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Capacity of a standing patient to reach a sitting position as defined by the test "Sit down" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to maintain a stand still position for 2 minutes as defined by the test "Stand without support for 2 minutes" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to lean with extended arm in a standing position (90° arms) at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Ability of the patient to perform a U-turn in less than 3 minutes as defined by the test "Make a U-turn" at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
  • Average scores on Borg CR-10 simple perception scale for the perceived exertion at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
    Rating of perceived exertion (RPE) is a widely used and reliable indicator to monitor and guide exercise intensity. The scale allows individuals to subjectively rate their level of exertion during exercise or exercise testing. Developed by Gunnar Borg, it is often also referred to as the Borg Scale. Despite being a subjective measure of exercise intensity, RPE scales provide valuable information when used correctly. The revised category-ratio scale (0 to 10 scale) is used:
    • 0 Null
    • 1 Very easy
    • 2 Somewhat easy
    • 3 Moderate
    • 4 Somewhat hard
    • 5 Hard
    • 6
    • 7 Very hard
    • 8
    • 9
    • 10 Very, very hard
  • Average scores of safety perceived by the patient on a 7-point Likert scale 7 levels at the 6th and 12th sessions. [ Time Frame: At study mid-term, 10 days in average and at study completion, up to 3 weeks ]
    A Likert scale is a psychometric scale commonly involved in research based on survey questionnaires. Here, the respondents specify their level of agreement or disagreement using a symmetric agree-disagree scale for a series of statements while responding to a particular Likert questionnaire item. The range of Likert scale captures the intensity of their feelings for a given item. The Likert scale ratings are:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
    The perceived safety is evaluated with the 7-point Likert scale on the following statement: "I felt safe during the test"
  • Observation of the skin condition was made before and after each session on the subject's back, thighs, knees and feet. [ Time Frame: Throughout study completion, an average of 3 weeks ]
  • Comparison of NBD score and Bristol scale before the 1st session and after the 12th session. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The neurogenic bowel dysfunction score is a questionnaire including questions about background parameters, faecal incontinence, constipation, obstructed defecation, and impact on quality of life. The NBD score is constructed from items with acceptable reproducibility and validity that were significantly associated with impact on quality of life. The type of the stool depends on the time it spends in the colon. The Bristol Stool Chart is:
    • Type 1: Separate hard lumps, like nuts (hard to pass);
    • Type 2: Sausage-shaped but lumpy;
    • Type 3: Like a sausage but with cracks on its surface;
    • Type 4: Like a sausage or snake, smooth and soft;
    • Type 5: Soft blobs with clear-cut edges (passed easily);
    • Type 6: Fluffy pieces with ragged edges, a mushy stool;
    • Type 7: Watery, no solid pieces. Entirety liquid.
    Type 1, 2 and 3 indicate constipation. Type 4 and 5 are ideal stools. Type 6 and 7 indicate diarrhea and urgency.
  • Definition of the voiding mode at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The management of neurogenic bladder dysfunction is crucial in the management of paraplegic patients as it affects the morbidity of these patients. The voiding mode is described. The self-survey is the standard treatment when the subject has an overactive bladder. The mictionnel mode will be informed before the first session, and at the end of the last session with the exoskeleton using an ISCOS questionnaire (International Spinal Cord Society questionnaire).
  • Qualiveen score at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Qualiveen score is developed as a condition-specific quality of life measurement for individuals with SCI who have urinary disorders. It contains 4 domains:
    • Limitation/ Inconvenience;
    • Constrains/ Restrictions;
    • Fears;
    • Feelings/ Impact on Daily Life.
    The test-retest reliability is high6.
  • Spasticity according to the Modified Ashworth scale at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Modified Ashworth Scale measures spasticity in patients with lesion of the Central Nervous System. The relationship between the raters' judgments was significant and the reliability was good. (PMID: 3809245) The scoring is:
    • 0: No increase in muscle tone
    • 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
    • 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
    • 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    • 3: Considerable increase in muscle tone, passive movement difficult
    • 4: Affected part(s) rigid in flexion or extension
    Muscles evaluated are adductor, hamstring, triceps sural and quadriceps.
  • Heart rate measurement at rest and after the 10mWT at the 1st, 6th and 12th sessions. [ Time Frame: At study start, day 1, at study mid-term, 10 days and at study completion, up to 3 weeks ]
  • Comparison of the Visual Analogue Pain Scale and NPSI scores at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    The Numeric Pain Rating Scale measures the subjective intensity of pain. The NPRS is an 11-points scale from 0 to 10: "0" = no pain; "10" = the most intense pain imaginable. The subject is asked to make pain rating corresponding to the current pain experienced. NPSI (Neuropathic Pain Sumptom Inventory) renders it suitable for the evaluation of the different dimensions of neuropathic pain syndromes. The reliability of the different descriptors appears to be sufficient. It allows to quantify the various pain symptoms that can be grouped into five dimensions (burn, deep pain, paroxysmal pain, pain caused, paresthesia / dysesthesia)
  • Patient Global Impression of Improvement (PGI-I) at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    The Patient Global Impression of Improvement (PGI-I) is a global index that may be used to rate the response of the use of Atalante on the bowel function. The subject should check the number that best describes how the twelfth session condition is, compared with how it has been at the first session for the bowel function:
    1. Very much better
    2. Much better
    3. A little better
    4. No change
    5. A little worse
    6. Much worse
    7. Very much worse
  • Average scores of the 7-point Likert scale for ergonomics at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    At the end of the twelfth session, the patient evaluates the interfaces and the ergonomics of Atalante (shape of the remote, mode, symbol) and the perceived safety and the level of assistance during transfer from the wheelchair to Atalante with a Likert scale. The Likert scale is a questionnaire where the subject chooses among seven-point scales:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
  • Time of installation of the patient in the exoskeleton at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
  • Assistance level for each fastener at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    The level of assistance is specified for each attachment (thigh, knee and foot straps). The levels of assistance are:
    • Without assistance;
    • With the assistance of one health professional;
    • With the assistance of two health professional.
  • Average scores of the 7-point Likert scale for exoskeleton attachment questionnaire at the 12th session. [ Time Frame: At study completion, up to 3 weeks ]
    At the end of the twelfth session, the strapping system is evaluated using a 7-point Likert scale:
    1. Strongly disagree
    2. Disagree
    3. Disagree somewhat
    4. Neither agree nor disagree
    5. Agree somewhat
    6. Agree
    7. Strongly agree
  • Evaluation of sitting balance using the Boubee test at the 1st and 12th sessions. [ Time Frame: At study start, day 1 and at study completion, up to 3 weeks ]
    This test evaluates the ability of the subject to balance in sitting position during disturbances induced by movements of the upper limbs. The subject is sitting without back's support and with both feet on the ground. The subject is asked to do six tasks from the easiest to the hardest. The subject must pass the task to test the next task. The score is defined by the last passed task. The sitting balance is evaluated at the first and at the last session.
  • Adverse events collection at each session. [ Time Frame: Throughout study completion, an average of 3 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis
Official Title  ICMJE Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis
Brief Summary

The study is a prospective, open, bicentric and observational study. It is conducted to assess the safety and performance of the Atalante exoskeleton system with patients with lower limb paralysis.

The principal objective is to assess the performance of the Atalante system in performing ambulatory functions with motor complete SCI patients characterized by the success rate in performing a 10mWT at the last session of training with the Atalante system.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Spinal Cord Injuries
  • Paraplegia
  • Paralysis, Lower Limbs
  • Lower Extremity
  • Robotics
Intervention  ICMJE Device: Use of the Atalante exoskeleton
A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
Study Arms  ICMJE Spinal Cord Injury patients with motor complete paralysis
Intervention: Device: Use of the Atalante exoskeleton
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 27, 2019)
12
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 16, 2018
Actual Primary Completion Date November 16, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Motor complete traumatic Spinal Cord Injury (AIS A and B) since at least 4 months
  • Spinal Injury Level between AIS T5 and AIS T12
  • Able to verticalize on a daily basis
  • Height: between approximately 1.60 and 1.90 m. More specifically, Atalante is able to accommodate the following limb lengths:

    • Thigh: 380-460 mm
    • Distance between the ground and the joint space of the knee (to be measured while wearing the shoes they intend to wear with Atalante):

      • 457-607 mm for patient with an ankle dorsiflexion ≥ 16°
      • 457-577 mm for patient with an ankle dorsiflexion between 13° et 16°
      • 457-567 mm for patient with an ankle dorsiflexion between 10° et 13°
      • 457-557 mm for patient with an ankle dorsiflexion between 0° et 10° o Hip width less of equal to 460 mm when seated
  • Maximum weight: 90 kg
  • Patient having given his written consent

Exclusion Criteria:

  • Patients whose joint centers cannot be aligned Atalante's
  • Ranges of motion below:

    • Hip: 115° flexion, 15° extension, 17° abduction, 10° adduction, 10° medial rotation, 20° lateral rotation
    • Knee: 5° extension, 110° flexion
    • Ankle: 0° dorsiflexion, 9° plantar flexion, 18° inversion and eversion
  • Severe spasticity (greater than 3 on the modified Ashworth scale) of the adductor muscles, hamstrings, quadriceps and triceps surae
  • Pregnant or lactating woman
  • Unbalanced psychiatric or cognitive status which may interfere with an appropriate use of the device
  • Other neurological disorder
  • History of osteoporotic fracture and/or disease or treatment responsible for a secondary osteoporosis
  • Active implantable medical device
  • Evolutive intercurrent disease: pressure sore, infection, venous thrombosis
  • Unstable and unhealed limb and pelvic fracture
  • Unstable spine
  • Severe illness which may interfere with the verticalized posture and tolerance to effort
  • Evolutive osteoma
  • Syringomyelia
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04110561
Other Study ID Numbers  ICMJE TPL005
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Wandercraft
Study Sponsor  ICMJE Wandercraft
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jacques Kerdraon, Dr Centre mutualiste de Rééducation et de Réadaptation de Kerpape
PRS Account Wandercraft
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP